6 10

Cited 0 times in

Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation

Authors
 Xiaoliang Zhao  ;  In-Kyu Kim  ;  Bhaskar Kallakury  ;  Joeffrey J Chahine  ;  Eiji Iwama  ;  Mariaelena Pierobon  ;  Emanuel Petricoin  ;  Justine N McCutcheon  ;  Yu-Wen Zhang  ;  Shigeki Umemura  ;  Vincent Chen  ;  Changli Wang  ;  Giuseppe Giaccone 
Citation
 MOLECULAR ONCOLOGY, Vol.15(4) : 1130-1145, 2021-04 
Journal Title
 MOLECULAR ONCOLOGY 
ISSN
 1574-7891 
Issue Date
2021-04
Keywords
Chk1 inhibitor ; Wee1 ; acquired resistance ; cell cycle
Abstract
Platinum-based chemotherapy has been the cornerstone treatment for small cell lung cancer (SCLC) for decades, but no major progress has been made in the past 20 years with regard to overcoming chemoresistance. As the cell cycle checkpoint kinase 1 (Chk1) plays a key role in DNA damage response to chemotherapeutic drugs, we explored the mechanisms of acquired drug resistance to the Chk1 inhibitor prexasertib in SCLC. We established prexasertib resistance in two SCLC cell lines and found that DNA copy number, messengerRNA (mRNA) and protein levels of the cell cycle regulator Wee1 significantly correlate with the level of acquired resistance. Wee1 small interfering RNA (siRNA) or Wee1 inhibitor reversed prexasertib resistance, whereas Wee1 transfection induced prexasertib resistance in parental cells. Reverse phase protein microarray identified up-regulated proteins in the resistant cell lines that are involved in apoptosis, cell proliferation and cell cycle. Down-regulation of CDK1 and CDC25C kinases promoted acquired resistance in parental cells, whereas down-regulation of p38MAPK reversed the resistance. High Wee1 expression was significantly correlated with better prognosis of resected SCLC patients. Our results indicate that Wee1 overexpression plays an important role in acquired resistance to Chk1 inhibition. We also show that bypass activation of the p38MAPK signaling pathway may contribute to acquired resistance to Chk1 inhibition. The combination of Chk1 and Wee1 inhibitors may provide a new therapeutic strategy for the treatment of SCLC.
Files in This Item:
T202101284.pdf Download
DOI
10.1002/1878-0261.12882
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, In-Kyu(김인규)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/182449
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links